DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Bernstein - 2 Shreyashi Sanyal - 2 Eileen Soreng - 2 Vas Narasimhan - 2 atrasentan - 2 Narasimhan - 2 Kisqali - 2 Miranda Murray - 2
Top related locs:
Bengaluru United States Europe Seattle Swiss IgAN San Francisco Royal Caribbean
Top related orgs:
Novartis - 5 Chinook Therapeutics - 5 Thomson - 4 Seattle - 3 ECB - 2 Adidas - 2 U.S . Federal Reserve - 2 European Central Bank - 2

Search resuls for: "Chinook Therapeutics"


6 mentions found


☆ German stocks lead gains in Europe, all eyes on central bank meetings
  + stars: | 2023-06-12 | by ( Shreyashi Sanyal Bansari Mayur Kamdar | Shreyashi Sanyal | Bansari Mayur Kamdar | ) www.reuters.com   time to read: +3 min
The pan-European STOXX 600 index (.STOXX) closed 0.2% higher, with the DAX (.GDAXI) up 0.9%. Luxury majors LVMH (LVMH.PA) and Hermes (HRMS.PA) climbed 1.8% and 3%, respectively, further supporting the STOXX 600. Meetings of the U.S. Federal Reserve, the European Central Bank and the Bank of Japan are lined up for the week. The STOXX 600 started the year on a stronger footing compared to the S&P 500 index (.SPX) but lost steam during the second quarter due to a rise in preference for growth-oriented stocks as opposed to value stocks. Shares in SES tumbled 14.6% to the bottom of the STOXX 600 after the satellite company announced its chief executive Steve Collar would step down.
Persons: BOJ, Bernstein, DAX, Lionel Messi's, Hermes, Daniela Hathorn, Sergio Ermotti, he’s, Michael Hewson, Silvio Berlusconi, Steve Collar, Shreyashi Sanyal, Bansari, Eileen Soreng Organizations: Fed, ECB, Adidas, UBS, CS, Inter Miami, U.S . Federal Reserve, European Central Bank, Bank of Japan, Credit Suisse, CMC Markets, MEDIAFOREUROPE, Italian, Novartis, Seattle, Chinook Therapeutics, SES, BNP, Exane, Thomson Locations: Europe, Bengaluru
☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States
☆ European shares rise at open, all eyes on c.bank meetings
  + stars: | 2023-06-12 | by ( ) www.reuters.com   time to read: +1 min
June 12 (Reuters) - European shares edged higher on Monday at the start of a week packed with major central bank policy meetings, while shares of Swiss drugmaker Novartis rose after it agreed to buy U.S.-based Chinook. The pan-European STOXX 600 index (.STOXX) rose 0.3% by 0715 GMT. Meetings from the U.S. Federal Reserve, the European Central Bank and the Bank of Japan are lined up for the week. The European healthcare sector index (.SXDP) was up 0.6%, while the personal & household sector index (.SXQP) led gains with a 0.9% rise. German sportswear maker Adidas (ADSGn.DE) jumped 3.1% after Bernstein raised its rating on the stock to "outperform" from "market perform".
Persons: Bernstein, Shreyashi Sanyal, Eileen Soreng Organizations: Swiss, Novartis, U.S . Federal Reserve, European Central Bank, Bank of Japan, ECB, Seattle, Chinook Therapeutics, Adidas, Thomson Locations: Bengaluru
☆ Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
June 12 (Reuters) - Novartis (NOVN.S) has agreed to acquire Seattle-based biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to dialysis or kidney transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, the company added. Additional reporting by Miranda Murray; Editing by Kim Coghill and Sonali PaulOur Standards: The Thomson Reuters Trust Principles.
Persons: Swiss drugmaker, Vas Narasimhan, atrasentan, Narasimhan, Kisqali, Soliris, Miranda Murray, Kim Coghill, Sonali Paul Organizations: Novartis, Seattle, Chinook Therapeutics, Chinook, Swiss pharma, Sandoz, Thomson Locations: Swiss, IgAN, United States
☆ Stocks making the biggest moves midday: Carnival, Nasdaq, Oracle, KeyCorp and more
  + stars: | 2023-06-12 | by ( Michelle Fox | ) www.cnbc.com   time to read: +3 min
The Carnival Miracle cruise ship operated by Carnival Cruise Line is docked at Pier 27 in San Francisco, Sept. 30, 2022. Other cruise stocks also got a boost, with Norwegian Cruise Line gaining about 9% and Royal Caribbean adding 2%. Chinook Therapeutics — Shares soared 58.32% after Novartis announced it has agreed to acquire the biotech firm for up to $3.5 billion. Oracle — Shares of the IT cloud software company gained 5.99% ahead of its quarterly earnings announcement scheduled for after the bell. Wolfe Research upgraded shares to outperform from peer perform in a Sunday note, citing the company's early-mover advantage in the artificial intelligence boom.
Persons: JPMorgan Chase, Thoma Bravo, Morgan Stanley, Wolfe, Alessandro Maselli, Nio, Nomura, Illumina, Francis deSouza, Carl Icahn, KeyCorp, — CNBC's Hakyung Kim, Alex Harring, Samantha Subin, Jesse Pound Organizations: Carnival Cruise, JPMorgan, Bank of America, Cruise Line, Royal, Chinook Therapeutics, Novartis, Nasdaq —, Thoma, Oracle —, Wolfe Research Locations: San Francisco, Royal Caribbean
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
0 next >>
Total: 6